Paper33712445
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P and 15 others. J Immunother Cancer, 2021. Cited by 173 papers, by iCite.
Cite this record
ConductScience Library. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Papers, record 33712445. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33712445
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Breast Neoplasms | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Glycyrrhizic Acid | Major topic |
| HMGB1 Protein | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Lung Neoplasms | Major topic |
| Peptide Fragments | Major topic |
| S100 Proteins | Major topic |
| Tumor Microenvironment | Major topic |
| Uterine Cervical Neoplasms | Major topic |
| Animals | |
| Female | |
| Humans | |
| Mice | |
| Adaptive Immunity | |
| Cell Line, Tumor | |
| Macrophages | |
| Mice, Inbred BALB C | |
| Mice, Inbred C57BL | |
| Mice, Nude | |
| RAW 264.7 Cells | |
| Signal Transduction | |
| Tumor Burden |
Source PubMed
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23243584 | Targeting PD-1/PD-L1 interactions for cancer immunotherapy. | Oncoimmunology | 2012 | https://conductscience.org/library/papers/23243584 | PubMed |
| 2 | 30345906 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30345906 | PubMed |
| 3 | 23811849 | Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. | Cell Death Differ | 2014 | https://conductscience.org/library/papers/23811849 | PubMed |
| 4 | 10952726 | High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. | J Exp Med | 2000 | https://conductscience.org/library/papers/10952726 | PubMed |
| 5 | 10398600 | HMG-1 as a late mediator of endotoxin lethality in mice. | Science | 1999 | https://conductscience.org/library/papers/10398600 | PubMed |
| 6 | 20370557 | Reactive oxygen species in cancer. | Free Radic Res | 2010 | https://conductscience.org/library/papers/20370557 | PubMed |
| 7 | 28848055 | Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis. | Cancer Immunol Res | 2017 | https://conductscience.org/library/papers/28848055 | PubMed |
| 8 | 22869893 | Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. | J Exp Med | 2012 | https://conductscience.org/library/papers/22869893 | PubMed |
| 9 | 22105604 | Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). | Mol Med | 2012 | https://conductscience.org/library/papers/22105604 | PubMed |
| 10 | 29658856 | Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29658856 | PubMed |
| 11 | 27383136 | HMGB1 Enhances Drug Resistance and Promotes In Vivo Tumor Growth of Lung Cancer Cells. | DNA Cell Biol | 2016 | https://conductscience.org/library/papers/27383136 | PubMed |
| 12 | 1846317 | Production of large amounts of hydrogen peroxide by human tumor cells. | Cancer Res | 1991 | https://conductscience.org/library/papers/1846317 | PubMed |
| 13 | 20547845 | A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20547845 | PubMed |
| 14 | 30796203 | Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1+ TAM expansion. | Oncogenesis | 2019 | https://conductscience.org/library/papers/30796203 | PubMed |
| 15 | 29700411 | A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. | Br J Cancer | 2018 | https://conductscience.org/library/papers/29700411 | PubMed |
| 16 | 18631454 | Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. | Immunity | 2008 | https://conductscience.org/library/papers/18631454 | PubMed |
| 17 | 27161491 | The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. | Nat Commun | 2016 | https://conductscience.org/library/papers/27161491 | PubMed |
| 18 | 22580958 | HMGB1 in development and diseases of the central nervous system. | Mol Neurobiol | 2012 | https://conductscience.org/library/papers/22580958 | PubMed |
| 19 | 27138582 | Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27138582 | PubMed |
| 20 | 29463549 | Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29463549 | PubMed |
Cited by125
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 173 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42980800 | HMGB1 expression in CT26 murine cancer cells modulates the tumor microenvironment and limits local anti-tumor immunity. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/42980800 | PubMed |
| 42840204 | GULP1 Fuels Resistance to PD-1 Blockade through Lipid-Mediated Metabolic Reprogramming of Tumor-Associated Macrophages in Gastric Cancer. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/42840204 | PubMed |
| 42812529 | Pan-Cancer Landscape of the Novel Oxygen Sensor ADO and Its Potential Role in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42812529 | PubMed |
| 42794625 | HMGB1 Post-Translational Modifications in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: Current Evidence, Emerging Mechanistic Concepts, and Unresolved Questions. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794625 | PubMed |
| 42737756 | Damage-Associated Molecular Patterns in Mesothelioma: Drivers of Inflammation and Therapeutic Targets. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737756 | PubMed |
| 42713311 | The double-edged sword of SASP in breast cancer: from tumor suppression to progression and therapy resistance. | Front Oncol | 2026 | https://conductscience.org/library/papers/42713311 | PubMed |
| 42633379 | DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42633379 | PubMed |
| 42591645 | Integrative analysis of HMGB3 in esophageal carcinoma: expression profile, prognostic significance, and immune microenvironment associations. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42591645 | PubMed |
| 42433356 | Lipopolysaccharide and HMGB1: key regulatory factors in the pathophysiology of sepsis a mechanistic and therapeutic review. | Front Immunol | 2026 | https://conductscience.org/library/papers/42433356 | PubMed |
| 42343654 | Revealing the Biological Effect of the N-glycosylation of High-Mobility Group Box 1 (HMGB1) Facilitated by Chemical Protein Synthesis. | J Am Chem Soc | 2026 | https://conductscience.org/library/papers/42343654 | PubMed |
| 42111273 | Recent Advances in Antitumor Nanomedicine Based on Covalent Organic Frameworks. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42111273 | PubMed |
| 42067772 | Context-dependent release of HMGB1: cell death mode, cell type and LPS stress drive monomer and heterocomplex formation. | Mol Med | 2026 | https://conductscience.org/library/papers/42067772 | PubMed |
| 42023220 | From immune desert to hot tumor: the tripartite synergy of tumor microenvironment-exosomes-immunogenic cell death in pioneering solutions. | Front Immunol | 2026 | https://conductscience.org/library/papers/42023220 | PubMed |
| 41998294 | Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics. | Apoptosis | 2026 | https://conductscience.org/library/papers/41998294 | PubMed |
| 41939886 | FLASH radiotherapy and immunotherapy synergy: mechanisms, strategies, and clinical translation prospects. | Front Immunol | 2026 | https://conductscience.org/library/papers/41939886 | PubMed |
| 41931634 | TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma. | JCI Insight | 2026 | https://conductscience.org/library/papers/41931634 | PubMed |
| 41924652 | HMGB1 as Double-Edged Regulator of Cancer Therapy: Mechanistic Roles in Chemotherapy Resistance and Immunotherapy Response. | Onco Targets Ther | 2026 | https://conductscience.org/library/papers/41924652 | PubMed |
| 41822488 | Prognostic significance and regulatory role of ACOT7 in the tumor immune microenvironment of breast invasive ductal carcinoma: a multi-omics analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/41822488 | PubMed |
| 41783547 | Dual-Action Theranostic Nanoparticles Delivering Toll-Like Receptor 2 Inhibitors and Chemotherapy Target Breast Cancer Cells and the Tumor Microenvironment. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41783547 | PubMed |
| 41688736 | The redox-sensitive protein HMGB1: intracellular and extracellular roles. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/41688736 | PubMed |
Genes34
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33712445
GET https://conductscience.org/api/papers/v1/33712445/references?page=2